NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trial
Bibliographic record
Abstract
Introduction: A high level of unmet need exists in the treatment of COPD patients. NVA237 (glycopyrronium bromide) is a once-daily (QD) long-acting muscarinic antagonist in development for the treatment of COPD. Methods: Patients with moderate-to-severe COPD were randomized (2:1) to 26 wks' double-blind treatment with NVA237 50 μg QD or placebo (PBO) administered via a low-resistance single-dose dry powder inhaler (Concept1 device). In addition to FEV 1 (primary endpoint: trough FEV 1 after 12 wks) efficacy was assessed by symptoms (via the transition dyspnea index [TDI]), HRQoL (via the St George's Respiratory Questionnaire [SGRQ]), and rescue medication use. Results: A total of 822 patients (mean age 63.9 yrs; post-bronchodilator FEV 1 54.6% predicted) were randomized; 80.5% completed. At Wk 26, NVA237 significantly increased total TDI focal score vs PBO (difference: 1.04, p<0.0001) exceeding the minimum clinically important difference ([MCID] ≥1 point). The% of patients achieving a MCID in TDI score was significantly higher with NVA237 vs PBO (62.5% vs 50.8%; odds ratio [OR] 1.74; p=0.001). NVA237 significantly reduced rescue medication use vs PBO after 26 wks of treatment (–0.46 puffs/day, p=0.005). SGRQ total score was significantly reduced with NVA237 vs PBO (–2.81; OR 1.58; p=0.004). The% of patients achieving a clinically meaningful improvement in SGRQ (≥4 point reduction) was significantly higher with NVA237 vs PBO (56.3% vs 46.0%; p=0.006). Conclusion: NVA237 50 μg once daily provided a significant and clinically relevant improvement in dyspnea at 26 wks vs PBO, which was accompanied by a significant improvement in HRQoL and reduced rescue medication use.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".